Carisma Therapeutics Profit Margin

The latest profit margin for CARM is 220.15% as of September 2025. That compares with -314.78% in the prior-year period — up 169.9% year over year. That is above the Healthcare sector average of 21.34%. Investors often review this figure alongside Carisma Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CARM's profit margin moved from -314.78% to 220.15% — a 169.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Carisma Therapeutics's valuation or profitability profile.

Against Healthcare companies, CARM currently prints 220.15% for profit margin, while the sector average sits near 21.34%. That is roughly 931.9% above the sector mean. Large gaps often invite a closer look at Carisma Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Carisma Therapeutics converts resources into returns. At 220.15%, CARM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -314.78% in the prior-year period — up 169.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CARM's profit margin (220.15%), review year-over-year change from -314.78%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.